Qlaris Phase 2 Study of QLS-111 in POAG and/or OHT Patients

Conditions:   Primary Open Angle Glaucoma (POAG);   Primary Open Angle Glaucoma of Both Eyes;   Primary Open-Angle Glaucoma, Unspecified Eye;   Ocular Hypertension (OHT) Interventions:   Drug: Experimental: QLS-111 ophthalmic solution, (0.015%);   Drug: Experimental: QLS-111 ophthalmic solution, (0.03%);   Drug: Experimental: QLS-111 ophthalmic solution, (0.075%);   Drug: Timolol maleate Preservative Free 0.5% ophthalmic solution;   Other: QLS-111 ophthalmic vehicle solu tion Sponsor:   Qlaris Bio, Inc. Not yet recruiting

Source: ClinicalTrials.gov - August 30, 2023 Category: Research Source Type: clinical trials